Clinical Trial

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2024-10-08; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2024-12-13
Trial Details
NCT Number NCT06634589
Lead Sponsor BeOne Medicines
Conditions B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Enrollment 80 participants
Start Date 2024-11-27
Primary Completion 2028-12-02 (estimated)
Study Completion 2029-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-23